What are the diagnostic criteria and treatment options for refractory cardiogenic shock?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Determining Refractory Cardiogenic Shock

Refractory cardiogenic shock is defined by persistent tissue hypoperfusion despite adequate doses of two vasoactive medications and treatment of the underlying etiology, with specific hemodynamic criteria including cardiac power output <0.6 W, cardiac index <2.2 L/min/m², and elevated lactate despite maximal medical therapy. 1, 2

Hemodynamic Criteria for Refractory Shock

The diagnosis requires invasive hemodynamic monitoring demonstrating:

  • Cardiac Power Output (CPO) <0.6 W - This is the most critical threshold for identifying refractory shock 1
  • Cardiac Index (CI) <2.2 L/min/m² despite vasopressor and inotropic support 1, 3
  • **Systolic Blood Pressure <80 mmHg** despite maximal treatment or requiring high-dose vasopressors to maintain SBP >90 mmHg 1
  • Elevated filling pressures: Pulmonary Capillary Wedge Pressure (PCWP) >15 mmHg in LV-dominant shock 1, 3
  • Right Atrial (RA) pressure patterns help differentiate phenotypes: RA >15 mmHg suggests RV involvement, while RA <15 mmHg suggests LV-dominant shock 1

Clinical Markers of Persistent Hypoperfusion

Beyond hemodynamics, refractory shock demonstrates ongoing end-organ dysfunction:

  • Elevated lactate levels (>2 mmol/L) that persist or worsen despite therapy 3, 4
  • Decreased urine output (<0.5 mL/kg/h) indicating renal hypoperfusion 3
  • Altered mental status from cerebral hypoperfusion 3
  • Cool extremities with livedo reticularis from peripheral vasoconstriction 5
  • Progressive multiorgan failure including hepatic dysfunction (bilirubin ≥1.3 mg/dL) 3

Phenotype-Specific Criteria

The determination of refractory shock must account for the specific ventricular failure pattern 1:

LV-Dominant Refractory Shock

  • CPO <0.6 W with PCWP >15 mmHg and RA <15 mmHg 1
  • Pulmonary Arterial Pulsatility Index (PAPi) >1.0 1

RV-Dominant Refractory Shock

  • CPO <0.6 W with RA >15 mmHg and PCWP <15 mmHg 1
  • PAPi <1.0 indicating RV failure 1

Biventricular Refractory Shock

  • CPO <0.6 W with both RA >15 mmHg and PCWP >15 mmHg 1
  • PAPi >1.0 but with elevated bilateral filling pressures 1

Temporal Criteria

The timing element is critical for defining refractory status:

  • Precardiotomy setting: Progressive deterioration requiring increasing doses of intravenous inotropes and/or IABP to maintain hemodynamic targets, with failure to wean from inotropes 1
  • Failure to wean from cardiopulmonary bypass: Prolonged weaning time >1 hour with deteriorating hemodynamics or cardiac arrest 1
  • Postcardiotomy setting: Persistent shock despite maximal medical therapy including inotropes and IABP 1

Contraindications to Escalation

Before labeling shock as truly refractory, exclude absolute contraindications to mechanical circulatory support 1:

  • Anoxic brain injury 1
  • Irreversible end-organ failure 1
  • Prohibitive vascular access 1
  • Do Not Resuscitate (DNR) status 1

SCAI Staging Context

Refractory shock typically corresponds to SCAI Stage D (deteriorating/doom) or Stage E (extremis) 3, 5:

  • Stage D: Worsening despite initial interventions, requiring multiple/high-dose pressors/inotropes, or mechanical support 3
  • Stage E: Cardiac arrest requiring ongoing CPR and/or ECMO 3

Practical Algorithm for Determination

  1. Confirm adequate treatment of underlying cause (e.g., revascularization for AMI) 2
  2. Document failure of two vasoactive medications at adequate doses 2
  3. Obtain invasive hemodynamics via pulmonary artery catheter showing CPO <0.6 W and CI <2.2 L/min/m² 1, 4
  4. Verify persistent hypoperfusion markers (lactate, urine output, mental status) 3, 4
  5. Identify shock phenotype (LV, RV, or biventricular) using RA pressure, PCWP, and PAPi 1
  6. Assess for contraindications to mechanical circulatory support 1
  7. Escalate to MCS consideration if no contraindications exist 1, 6

Common Pitfalls

  • Delaying invasive monitoring: Early pulmonary artery catheter placement is essential for accurate phenotyping and should not be delayed 4, 5
  • Inadequate treatment of underlying cause: Shock may appear refractory when the primary lesion (e.g., ongoing ischemia, mechanical complication) remains untreated 2
  • Confusing late septic shock with cardiogenic shock: Septic shock can develop myocardial depression but maintains decreased SVR as the primary pattern 3
  • Prolonged attempts at medical optimization: Application of IABP within 30 minutes and MCS within 1 hour from first weaning attempts is suggested to prevent complications 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Management of refractory cardiogenic shock.

Nature reviews. Cardiology, 2016

Guideline

Hemodynamic Differentiation of Shock Types

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Shock

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Cardiogenic Shock and Severe Congestive Heart Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.